Prognostic impact of spread through air spaces in lung adenocarcinoma

Sara Mantovani (a), Angelina Pernazza (b), Massimiliano Bassi (a), Davide Amore (a), Jacopo Vannucci (a), Camilla Poggi (a), Daniele Diso (a), Giulia d’Amati (c), Carlo Della Rocca (c), Erino Angelo Rendina (a), Federico Venuta (a) and Marco Anile (a,*)

(a) Department of Thoracic Surgery, University of Rome Sapienza, Rome, Italy
(b) Department of Medical-Surgical Sciences and Biotechnologies, University of Rome Sapienza, Rome, Italy
(c) Department of Radiological, Oncological and Pathological Sciences, University of Rome Sapienza, Rome, Italy

* Corresponding author. Department of Thoracic Surgery, University of Rome Sapienza, Viale del Policlinico 155, Rome 00161, Italy. Tel: +39-0649970162; fax: +39-0649970220; e-mail: marco.anile@uniroma1.it (M. Anile).

Received 6 January 2021; received in revised form 1 September 2021; accepted 9 September 2021

Abstract

OBJECTIVE: Spread through air spaces (STAS) is a pattern of invasion present in some adenocarcinomas (ADC). The goal of this study was to assess the impact of STAS in patients treated with different types of surgical resections and on the clinical outcome in patients with ADC of different diameters and with different degrees of nodal involvement.

METHODS: A total of 109 patients were reviewed. Complete surgical resection with systematic nodal dissection was achieved in all patients. The median follow-up was 65 months (3–90 months).

RESULTS: STAS was observed in 70 cases (64.2%); 13 patients (18.5%) had lymph node involvement (N1 and N2). Overall survival and progression-free survival were higher in patients without STAS (P = 0.042; P = 0.027). The presence of STAS in tumours ≤2 cm was a predictor of worse progression-free survival following sublobar resection compared to major resections (P = 0.011). Sublobar resection of N0

Key question
Could spread through air spaces (STAS) influence the prognosis of early-stage lung adenocarcinoma?

Key finding(s)
STAS seems to play a role in long-term survival, particularly for patients with N0 and those with tumours smaller than 2 cm.

Take-home message
STAS could be considered a new factor to predict prognosis in early-stage lung adenocarcinoma that has undergone limited resections.
STAS-positive tumours was associated with worse long-term survival compared to a major resection (P = 0.04). Statistical analyses showed that age >70 years and recurrence were independent variables for survival; smoking pack-years >20, sublobar resection and nodal involvement were independent variables for recurrence; and smoking pack-years >20 were independent variables for a history of cancer and pleural invasion for local recurrence.

CONCLUSIONS: STAS seems to play a role in long-term survival, particularly for patients with N0 and tumours smaller than 2 cm. Further studies are necessary to validate this hypothesis.

Keywords: Adenocarcinoma • STAS • Pulmonary resections • Lymph node involvement

ABBREVIATIONS

| ADC | Adenocarcinomas |
|-----|----------------|
| STAS| Spread through air spaces |

INTRODUCTION

Spread through air spaces (STAS) of adenocarcinoma (ADC) is a peculiar pattern of local invasion acknowledged by the last World Health Organization classification [1]. According to the original definition, it comprises tumour cells (forming either micropapillary structures or solid nests or appearing as isolated cells) spreading within air spaces beyond the tumour edge without direct connection with the primary tumour [2].

Although this concept has been challenged by some authors [3], STAS should be considered a negative prognostic factor in stage I ADC; it is able to predict recurrence in case of both sublobar resection and lobectomy [2, 4, 5]. However, some points still remain controversial. In fact, the exact mechanism underlying STAS and the prognostic impact at more advanced stages are still to be defined. In addition, although it has been recently reported that STAS is a predictor of occult lymph node metastases in clinical stage I ADC [6], the relationship with lymph node involvement has not been clarified. Finally, the gold standard treatment for STAS positive ADC is still to be defined [7].

The goal of this retrospective study was to assess the prognostic impact of STAS in patients undergoing different types of surgical resections and to correlate it with the diameter of the tumour and the extent of nodal involvement.

MATERIALS AND METHODS

The database included 124 patients with lung ADC undergoing pulmonary resection. Fifteen patients were lost to follow-up; the remaining patients were assessed by a clinical visit or a telephone interview. Inclusion criteria were age >18 years and pulmonary resection for ADC. The study period included cases treated and retrospectively reviewed by pathologists from January 2013 to September 2015. The mean age was 68.9 ± 10.1 years; the male/female ratio was 1.4/1 (63/46); 38 (35%) were smokers, 48 (44%) were former smokers and 23 (21%) never smoked. Fifty-seven female ratio was 1.4/1 (63/46); 38 (35%) were smokers, 48 (44%) were former smokers and 23 (21%) never smoked. September 2015. The mean age was 68.9 ± 10.1 years; the male/female ratio was 1.4/1 (63/46); 38 (35%) were smokers, 48 (44%) were former smokers and 23 (21%) never smoked. Fifty-seven

The requirement to reliably evaluate STAS in the surgical specimen was the presence of a circumferential rim of normal lung (at least 1 cm) surrounding the edge of the tumour. Accordingly, we had previously selected from our retrospective cases those in which the tumour periphery adjacent to normal lung tissue was present in at least 1 histological slide. From 2 to 7 haematoxylin and eosin slides were available from each sample and were reviewed by 2 expert pathologists (GdA and AP). Cases were divided into 2 groups: STAS positive and STAS negative. In STAS positive tumours, the morphological pattern was detailed as follows: micropapillary clusters, solid nests or single cells. Finally, to assess whether the extension of STAS could be a prognostic factor, the cases were categorized as low STAS (involving up to 2/3 of the tumour circumference) and high STAS (involving the entire tumour circumference) (Fig. 1).

Statistical analysis

The independent variables analysed for survival and recurrence were age (cut-off 70 years), gender, history of smoking, previous history of malignancy, comorbidities, radiological features of ground-glass opacity, diameter of the tumour (cut-off 20 mm), lymph node involvement, staging, grade of differentiation of
cancer, presence of STAS, extension of STAS (low versus high), lymphatic invasion, pleural invasion, histological patterns (acinar, lepidic, papillary, solid, micropapillary, cribriform, mucinous), induction therapy, adjuvant therapy and type of surgery (sublobar resection versus other). Continuous variables were shown as mean ± standard deviation whereas categorical variables were presented as number and percentages; the Student’s t-test and the χ² test were used according to the variables. Cox regression analysis was performed to assess the impact of the different variables on survival and on the incidence of local and overall recurrence (considered local plus distant). The overall and the progression-free survival curves were determined using a Kaplan–Meier analysis. The log-rank test was used to compare survivals. A P-value <0.05 was considered statistically significant. The statistical analysis was performed using SPSS 17.0 software (IBM-SPSS Statistics, Armonk, NY, USA).

RESULTS

The median follow-up was 65 months (3–90 months). Demographic data are reported in Table 1. No perioperative deaths were observed; the mean time from the operation to hospital discharge was 7.8 ± 4.6 days. Twenty-two patients (20.2%) showed postoperative complications, mainly persistent air leaks (9–40.9%) and atelectasis (4–18.1%). According to the 8th staging system, 72 patients (66.1%) were stage I; 17 (15.6%) were stage II; and 20 (18.3%) were stage IIIA. Twenty-three patients (21.1%) received adjuvant chemotherapy; 11 of them (47.8%) also received radiotherapy. We observed 37 recurrences (34%); 14 of them (37.3%) were considered local.

Table 1: Characteristics of the study cohort

| Variables                        | Number of patients | Percentage |
|----------------------------------|--------------------|------------|
| Age, median (range)              | 68.9 (39–86)       |            |
| <70                              | 59                 | 54.1       |
| ≥70                              | 50                 | 45.9       |
| Sex                              |                    |            |
| Male/female                      | 63/46              | 57.8/42.2  |
| Smokers                          |                    |            |
| No                               | 23                 | 21.1       |
| Yes-Ex                           | 86                 | 78.9       |
| Surgery                          |                    |            |
| Major resection                  | 83                 | 76.1       |
| Sublobar resection               | 26                 | 23.9       |
| Tumour size                      |                    |            |
| <20 mm                           | 48                 | 56         |
| ≥20 mm                           | 61                 | 44         |
| N stage                          |                    |            |
| N0                               | 92                 | 84.4       |
| N1–N2                            | 17                 | 15.6       |
| Angiolympathic Invasion          |                    |            |
| Y/N                              | 8/101              | 7.3/92.3   |
| Pleural invasion                 |                    |            |
| Y/N                              | 33/76              | 30.3/69.7  |
The mean diameter of the tumours was $23.9 \pm 15.6$ mm. Sixteen patients (14.7%) had well differentiated ADC; 71 (65.1%) had moderately differentiated ADC; and 22 (20.2%) had poorly differentiated ADC (Table 2). STAS was observed in 70 cases (64.2%). The mean diameter of tumours showing STAS was significantly higher than that of the STAS-negative tumours ($26.6 \pm 15.3$ vs $19.2 \pm 15.03$ mm; $P = 0.01$). In 41 cases (58.6%), STAS showed micropapillary features; in 15 (21.4%), it showed a solid pattern; and in 14 (20%), it occurred as single cells; 57 cases (81.4%) were classified as ‘low STAS’ and 13 (18.6%), as ‘high STAS’. Seventeen patients (15.6%) had lymph node involvement (N1 and N2); 13 of them (76.4%) had STAS. Lymphatic and pleural invasions were observed in 8 (7.3%) and 33 (30.3%) cases, respectively.

Overall 5-year and progression-free survival was $57 \pm 5$ and $53.6 \pm 5\%$, respectively; the survival curves differed overall, with $P = 0.042$ and $P = 0.027$, respectively, with survival rates at 5 years higher in patients without STAS ($72 \pm 6\%$ vs $46 \pm 6\%$ and $71 \pm 5\%$ vs $42.1 \pm 4\%$). When we compared overall survival according to the type of resection (sublobar versus major resections), we found no significant difference between patients with and without STAS ($P = 0.1$). However, the presence of STAS in tumours smaller than 2 cm was a significant predictor of worse progression-free survival at 5 years in patients undergoing sublobar resection compared to those having major resections ($52.6 \pm 13.5\%$ vs $89.7 \pm 7\%; P = 0.011$). In addition, in N0 STAS-positive tumours, sublobar resection was associated with worse long-term survival compared to major resection ($24.2 \pm 13\%$ vs $56.1 \pm 8\%$; $P = 0.04$) (Fig. 2) and to a more negative trend regarding progression-free survival ($60 \pm 15\%$ vs $79.9 \pm 7\%; P = 0.06$). No significant difference in 5-year survival and progression-free survival was observed between patients with low STAS and those with high STAS.

With the $\chi^2$ test, age >70 years, the ground-glass opacity feature, diameter of the tumour > 20 mm, low grade of tumour differentiation, presence of STAS and a high STAS rate, adjuvant therapy, nodal involvement and recurrence were associated with a higher risk of death. Recurrence was associated with age >70 years, smoking pack-years >20, diameter of the tumour >20 mm, low grade of tumour differentiation, presence of STAS, nodal involvement and pleural invasion.

As reported in Table 3, Cox regression showed that age >70 years and recurrence were independent variables for survival, smoking pack-years >20, sublobar resection and nodal involvement were independent variables for recurrence and smoking pack-years >20, a history of cancer and pleural invasion were independent variables for local recurrence.

**DISCUSSION**

STAS is observed in a large percentage of patients with ADC [4]. Kadota et al. [1] in 2015 described STAS as a solid nest of tumour cells called a ‘tumour island’ in the alveolar spaces. Subsequently, several authors presented a number of retrospective studies identifying STAS as a negative prognostic factor impacting overall survival and onset of recurrence [5–13].

One of the goals of our study was to investigate whether STAS plays a role in determining the type of resection for patients with early-stage lung ADC. We have also investigated the impact of STAS on recurrence and survival in 2 different surgical settings: major lung resections and sublobar resections. We have stratified patients by TNM into 4 groups according to lymph node involvement (N0 or N1–N2) and STAS status (positive or negative), and we have compared them according to the type of surgical resection. We have assumed that in N0 patients, STAS could be an important prognostic factor for survival and recurrence. In fact, in locally advanced tumours, the presence of STAS does not affect prognosis in any group of patients (neither limited nor major resections); however, N0 patients with STAS undergoing sublobar resection showed an overall survival significantly worse and a higher risk of recurrence compared to N0 sublobar resections without STAS. According to our results, in patients with stage I lung ADC and STAS, a limited resection is associated with a significantly higher risk of recurrence and lower survival than a major resection. Kadota

**Table 2: Classification of histological subtypes**

| Histological subtypes   | Number of patients | Percentage |
|-------------------------|--------------------|------------|
| Acinar                  | 68                 | 62.4       |
| Lepidic                 | 20                 | 18.3       |
| Papillar                | 6                  | 5.5        |
| Solid                   | 8                  | 7.4        |
| Micropapillary          | 2                  | 1.8        |
| Cribriform              | 1                  | 0.9        |
| Mucin secreting         | 4                  | 3.7        |

**Figure 2:** Kaplan–Meier curves of sublobar and major resections in patients N0 spread through air spaces-positive compared by the log-rank test ($P = 0.04$).
et al. [14] published similar conclusions in 2019; they found that in patients with STAS, limited resection was associated with a significantly higher risk of loco-regional recurrence than lobectomy.

Moreover, we have explored the synergistic effects of STAS and tumour size on progression free survival. Patients have been classified into 4 groups according to tumour size and STAS status. We found that in patients with small tumours (<20 mm), the presence of STAS strongly influenced (or significantly predicted) the onset of recurrence compared to tumours >20 mm. These data not only provide further evidence to support the impact of this pattern of local invasion but they also suggest that STAS could be considered as a parameter to be included in the staging system to predict prognosis, particularly in regard to smaller tumours. However, further studies on a large study sample are required to validate this hypothesis. An intriguing result of our study is the finding that STAS was more frequent than previously reported [2, 13]. We believe that this finding is related to our extensive sampling of the lung parenchyma surrounding the neoplastic lesion.

Dai et al. [6] reported that STAS could predict the prognosis of patients with ADC between 2 and 3 cm; furthermore, a larger study by Eguchi et al. [15] showed that the 5-year cumulative incidence of recurrence and the cumulative incidence of lung cancer-specific death in patients with an ADC up to 2 cm in diameter was stratified by STAS. Based on these data and on the published literature, we suggest that STAS should be included when assessing the prognosis of patients with ADC. Unfortunately, STAS cannot yet be identified reliably at the pre-operative work-up, and the sensitivity and negative predictive value of frozen sections for STAS detection are still low [16].

Limitations

Some limitations of this study should be addressed, namely its single-centre retrospective nature and the relatively small population of patients; multicentre studies should be performed to confirm our results.

CONCLUSIONS

This study provides preliminary evidence that STAS could be considered a new factor in a staging system to predict prognosis more accurately, particularly in patients with NO and in tumours smaller than 2 cm. We have shown that in the subgroup of patients with ADC and STAS, limited resection is associated with a significantly higher risk of recurrence and lower survival; this observation should be considered when planning surgery.

Funding

No funding was requested for this study.

Conflict of interest: none declared.

Author contributions

Sara Mantovani: Data curation; Writing—original draft. Angelina Pernazza: Conceptualization; Data curation. Massimiliano Bassi: Formal analysis. Davide Amore: Data curation. Jacopo Vannucci: Validation; Writing—review & editing. Camilla Poggia: Investigation. Daniele Diso: Supervision. Giulia d’Amati: Data curation; Supervision; Validation; Writing—review & editing. Carlo Della Rocca: Supervision; Writing—review & editing. Erino Angelo Rendina: Supervision. Federico Venuta: Supervision. Marco Anile: Conceptualization; Data curation; Methodology; Validation; Writing—review & editing.

Reviewer information

Interactive CardioVascular and Thoracic Surgery thanks Ayten Kayi Cangir, David G. Healy and the other, anonymous reviewer(s) for their contribution to the peer review process of this article.

REFERENCES

[1] Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB et al.; WHO Panel. The 2015 WHO classification of lung tumors. Impact of genetic, clinical and radiological advances from 2004. J Thorac Oncol 2015;10:1243–60.
[2] Kadota K, Hitadori J, Sima CS, Ujiiie H, Rizk NB, Jones DR et al. Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences following limited resection for small stage I lung adenocarcinoma. J Thorac Oncol 2015;10:806–14.
[3] Blaauwgeers H, Russell PA, Jones KD, Radonica T, Thunnissen E. Pulmonary loose tumor tissue fragments and spread through air spaces (STAS): invasive pattern or artifact? A critical review. Lung Cancer 2018;123:107–11.
[4] Toyokawa G, Yamada Y, Tagawa T, Oda Y. Significance of spread through air spaces in early-stage lung adenocarcinomas undergoing limited resection. Thorac Cancer 2019;9:1255–61.
[5] Wert A, Muley T, Kossakowski CA, Goeppert B, Schirmacher P, Dienemann H et al. Prognostic impact of intra-alveolar tumor spread in pulmonary adenocarcinoma. Am J Surg Pathol 2015;39:793–801.
[6] Dai C, Xie H, Su H, She Y, Zhu E, Fan Z et al. Tumor spread through air spaces affects the recurrence and overall survival in patients with lung adenocarcinoma >2 to 3 cm. J Thorac Oncol 2017;12:1052–60.
[7] Vaghjiani RG, Takahashi Y, Eguchi T, Lu S, Kameda K, Tano Z et al. Tumor spread through air spaces is a predictor of occult lymph node metastasis in clinical stage I A lung adenocarcinoma. J Thorac Oncol 2020;15:792–802.
[8] Lardinoini D, De Leyn P, Van Schil P, Rami Porta R, Waller D, Passlick B et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 2006;30:767–92.
[9] Guo J, Liu Y, Tian X, Ren Z, Lin J, Wang B et al. Less is more in solid-dominant lung cancer? Sublobar resection versus lobectomy for solid-dominant stage IA non-small-cell lung cancer: a meta-analysis study. Mol Clin Oncol 2019;11:465–73.
[10] Chen D, Mao Y, Wen J, She Y, Zhu E, Zhu F et al. Tumor spread through air spaces in non-small cell lung cancer: a systematic review and meta-analysis. Ann Thorac Surg 2019;108:945–54.
[11] Shiono S, Yanagawa N. Spread through air spaces is a predictive factor of recurrence and a prognostic factor in stage I lung adenocarcinoma. Interact CardioVasc Thorac Surg 2016;23:567–72.
[12] Hu SY, Hsieh MS, Hsu HH, Tsai TM, Chiang XH, Tsou KC et al. Correlation of tumor spread through air spaces and clinicopathological characteristics in surgically resected lung adenocarcinomas. Lung Cancer 2018;126:189–93.
[13] Warth A. Spread through air spaces (STAS): a comprehensive update. Transl Lung Cancer Res 2017;6:501–7.
[14] Kadota K, Kushida Y, Kagawa S, Ishikawa R, Ibuki E, Inoue K et al. Loco-regional recurrence than lobectomy in stage I lung adenocarcinoma with tumor spread through air spaces. Ann J Surg Pathol 2019;43:1033–41.
[15] Eguchi T, Kameda K, Lu S, Bott MJ, Tan KS, Montecalvo J et al. Lobectomy is associated with better outcomes than sublobar resection in spread through air spaces (STAS)-positive T1 lung adenocarcinoma: a propensity score–matched analysis. J Thorac Oncol 2019;14:87–98.
[16] Walts AE, Marchevsky AM. Current evidence does not warrant frozen section evaluation for the presence of tumor spread through alveolar spaces. Arch Pathol Lab Med 2018;142:59–63.